These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8162495)

  • 21. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
    Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteinuria as complication of simvastatin treatment.
    Deslypere JP; Delanghe J; Vermeulen A
    Lancet; 1990 Dec; 336(8728):1453. PubMed ID: 1978916
    [No Abstract]   [Full Text] [Related]  

  • 23. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
    Cheng H; Rogers JD; Sweany AE; Dobrinska MR; Stein EA; Tate AC; Amin RD; Quan H
    Pharm Res; 1992 Dec; 9(12):1629-33. PubMed ID: 1488408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake.
    Vasconcelos OM; Campbell WW
    Muscle Nerve; 2004 Dec; 30(6):803-7. PubMed ID: 15389654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of cerebrotendinous xanthomatosis.
    Federico A; Dotti MT
    Neurology; 1994 Nov; 44(11):2218. PubMed ID: 7970001
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.
    Arnadottir M; Eriksson LO; Thysell H; Karkas JD
    Nephron; 1993; 65(3):410-3. PubMed ID: 8289991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinically manifest liver lesions during use of simvastatin].
    Koornstra JJ; Ottervanger JP; Fehmers MC; Stricker BH
    Ned Tijdschr Geneeskd; 1996 Apr; 140(15):846-8. PubMed ID: 8668280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute cholestatic hepatitis during simvastatin administration.
    Ballaré M; Campanini M; Catania E; Bordin G; Zaccala G; Monteverde A
    Recenti Prog Med; 1991 Apr; 82(4):233-5. PubMed ID: 1857844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depressive symptoms and cholesterol-lowering drugs.
    Duits N; Bos FM
    Lancet; 1993 Jan; 341(8837):114. PubMed ID: 8093380
    [No Abstract]   [Full Text] [Related]  

  • 31. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin therapy and CHD.
    Tobert JA
    Lancet; 1996 Jan; 347(8994):128. PubMed ID: 8538331
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 35. [Simvastatin in the treatment of hypercholesterolemia].
    Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
    Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
    Pentikainen PJ; Saraheimo M; Schwartz JI; Amin RD; Schwartz MS; Brunner-Ferber F; Rogers JD
    J Clin Pharmacol; 1992 Feb; 32(2):136-40. PubMed ID: 1613123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMG-CoA reductase inhibitor treatment in renal insufficiency.
    Wanner C
    Nephrol Dial Transplant; 1996 Oct; 11(10):1951-2. PubMed ID: 8918704
    [No Abstract]   [Full Text] [Related]  

  • 38. [Psychiatric disorders with use of simvastatin].
    Duits N; Bos FM
    Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1312-5. PubMed ID: 8345888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study.
    Capurso A; Resta F; Bertolini S; Masturzo P; Feruglio FS; Cattin L; Da Col PG; Descovich GC; Gaddi A; Urbinati GC
    Eur Heart J; 1992 Jul; 13 Suppl B():11-6. PubMed ID: 1644094
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.
    Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A
    Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.